Karyopharm Therapeutics | KPTI - Current Assets


Karyopharm Therapeutics reported $126.33M in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
AbbVie USD 37.48B 3.81B Sep/2026
Abbott USD 23.5B 1.02B Sep/2026
Amgen USD 34.36B 598M Sep/2026
AstraZeneca USD 31.45B 3.48B Sep/2026
BioCryst Pharmaceuticals USD 531.15M 46.47M Sep/2026
Bristol-Myers Squibb USD 29.77B 1.19B Sep/2026
Eli Lilly USD 65.26B 591M Sep/2026
Enanta Pharmaceuticals USD 198.68M 5.65M Dec/2025
GlaxoSmithKline GBP 17.9B 336M Sep/2026
Incyte USD 5.52B 505.2M Sep/2026
J&J USD 56.35B 3.42B Sep/2026
Karyopharm Therapeutics USD 126.33M 23.19M Mar/2026
MacroGenics USD 321.69M 139.16M Jun/2026
Merck USD 38.94B 2.26B Sep/2026
Nektar Therapeutics USD 589.04M 322.77M Mar/2026
Novartis USD 28.75B 1.4B Sep/2026
Novartis USD 28.75B 2.14B Sep/2026
Pfizer USD 45.01B 3.65B Sep/2026
Regeneron Pharmaceuticals USD 20.8B 2.35B Sep/2026
Roche Holding CHF 35.44B 3.29B Jun/2026
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Takeda JPY 3T 153.11B Sep/2026
Tectonic Therapeutic USD 231.1M 8.79M Jun/2026
TG Therapeutics USD 1.15B 58.72M Jun/2026
Ultragenyx Pharmaceutical USD 544M 62M Sep/2026
Xencor USD 498.66M 24.55M Sep/2026